News tagged with lung growth
New therapeutic target for lung cancer
A new therapeutic target for lung cancer has been discovered by researchers at Seoul National University. It was found that a variant of the protein AIMP2 is highly expressed in lung cancer cells and also that patients demonstrating ...
Mar 31, 2011 |
not rated yet |
0
Study reveals how lung cancers evolve in response to targeted treatment
A detailed analysis of lung tumors that became resistant to targeted therapy drugs has revealed two previously unreported resistance mechanisms. In a report in the March 23 Science Translational Medicine, investigators from t ...
Mar 23, 2011 |
not rated yet |
0
Researchers develop synthetic compound that may lead to drugs to fight pancreatic, lung cancer
Researchers at UT Southwestern Medical Center have identified a chemical compound that may eventually lead to a drug that fights cancers that are dependent on a particular anti-viral enzyme for growth.
Mar 09, 2011 |
not rated yet |
0
Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.
Feb 25, 2011 |
5 / 5 (1) |
0
Researchers provide genetic evidence that antioxidants can help treat cancer
Researchers from Jefferson's Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because ...
Feb 15, 2011 |
4.7 / 5 (7) |
0
|
AstraZeneca cancer drug carries toxic risks: FDA
An experimental drug developed by AstraZeneca to treat a rare form of thyroid cancer carries "substantial toxicity" risks, the US Food and Drug Administration warned Tuesday.
Medicine & Health / Medications
Nov 30, 2010 |
not rated yet |
0
Could lung cancer in smokers vs. 'never-smokers' be different diseases?
Lung tumors in those who smoke and those who never smoked have different DNA alterations in the tumor genomes, according to results of a pilot study presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research ...
Nov 08, 2010 |
5 / 5 (1) |
0
New targeted lung cancer drug produces 'dramatic' symptom improvement
A clinical trial of a potential new targeted treatment drug has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality. In their report ...
Oct 27, 2010 |
not rated yet |
0
Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, ...
Oct 12, 2010 |
5 / 5 (1) |
1
Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results ...
Oct 09, 2010 |
not rated yet |
0
African-Americans equally likely to benefit from erlotinib and other targeted lung cancer therapy
African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted ...
Sep 28, 2010 |
not rated yet |
0
Micro-RNA determines malignancy of lung cancer
A small RNA molecule determines whether or not lung cancer cells grow invasively and metastasize. This has been discovered in the culture dish by scientists of the German Cancer Research Center and the University Medical ...
Sep 08, 2010 |
5 / 5 (1) |
0
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according ...
Jun 05, 2010 |
not rated yet |
0
Blood test may identify lung cancer patients likely to respond to erlotinib
Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, ...
Apr 30, 2010 |
not rated yet |
0
Spanish gene expression data promise targeting of anti-angiogenesis treatment
Analyzing the expression of particular genes in lung cancers could soon allow researchers to identify groups of patients who are likely to benefit most from treatment with angiogenesis-inhibitor drugs, a Spanish team reports.
Apr 29, 2010 |
not rated yet |
0
